Skip to Late-Breaking Abstracts »
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
|P426||A first-in-human phase 1, multicenter trial of toll-like receptor (TLR) 7 agonist DSP-0509 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors||Shadia Jalal, MD; Jared Weiss, MD; Anthony J. Olszanski, MD, RPh; Jordan Berlin, MD; Makoto Origuchi; Zhonggai Li; Bella Ertik; Hongliang Cai; Daniel Clancy; Jose Iglesias; Vivek Subbiah, MD; Shadia Jalal, MD;||Clinical Trial In Progress||Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR|